domingo, 14 de junio de 2015

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. - PubMed - NCBI

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing. - PubMed - NCBI



 2015 Jul;55(7):725-7. doi: 10.1002/jcph.492.

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.


PMID:
 
26053647
 
[PubMed - in process]

No hay comentarios: